Portfolio PR – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

ARTHEx biotech

ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

2026.07.232026.07.23 / New data show systemic delivery of antimiR-23b developed on Arthex BOOST-ON™ platform reaches the brain, corrects disease biology, and improves behavior—highlighting potential to address CNS manifest ...

Theolytics

Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies

2026.07.162026.07.16 / Oxford UK, July 14th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilitie ...

Simon Mølgaard Named Rising Star in Danish Biotech

2026.06.292026.06.29 / We are proud to congratulate Simon Mølgaard, CEO of our portfolio company Teitur Trophics, on being awarded the Rising Star in Danish Biotech at the Biotech Spring Gala — with the recognition display ...

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

2026.06.252026.06.29 / Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained improvements in cardiac output, structure and function STOCKHOLM, Sweden, [D ...

ARTHEx biotech

ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)

2026.05.272026.05.27 / Valencia, Spain, May 27, 2026 — Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced multiple presentations at the ...

AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF

2026.05.112026.05.18 / STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), ...

Teitur Trophics CEO Simon Mølgaard Receives Rising Star Award at Biotech Spring Gala

2026.05.072026.05.18 / We are pleased to congratulate Simon Mølgaard, CEO of Teitur Trophics, on receiving the Rising Star Award at this year’s Biotech Spring Gala. The award, presented by DANISH BIO – Dansk Biotek, rec ...

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

2026.05.052026.05.05 / Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and ...

Theolytics

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

2026.04.282026.05.18 / OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1 ...

AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

2026.03.262026.03.26 / STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have ...

Boost Pharma

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

2026.03.192026.03.19 / Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imp ...

Hans Schambye - Boost Pharma

Developing possibly the first disease-modifying pediatric treatment for an agonizing condition

2026.03.162026.05.18 / BOOST Pharma aims to advance the development of a novel off-the-shelf cell therapy for children with an excruciating disease. And CEO Hans Schambye is leading the company onward to make it a reality. ...